Veracyte Q3 EPS Beats by 59% on $131.8M Revenue; Zacks #1 Rank
Veracyte posted Q3 2025 EPS of $0.51, 59.4% above consensus, and revenue of $131.8 million, beating estimates by 5.5%. It carries a Zacks #1 rank with an estimated 2026 earnings recession rate of 3% versus a 17.5% industry increase and has averaged 45.1% earnings surprises over the past four quarters.
1. Third-Quarter 2025 Performance
Veracyte reported Q3 adjusted EPS of $0.51, exceeding consensus by 59.4%, and delivered revenue of $131.8 million, outpacing analyst estimates by 5.5%. This marks the fourth consecutive quarter of positive earnings surprises, with an average beat of 45.1%.
2. Zacks #1 Ranking and Investor Confidence
The company holds a Zacks #1 (Strong Buy) rank, reflecting strong analyst sentiment and growth expectations based on consistent earnings outperformance and robust revenue trends. This top-tier ranking may attract increased institutional interest and enhance market visibility.
3. 2026 Earnings Outlook
Veracyte faces an estimated earnings recession rate of just 3% for 2026 versus a 17.5% industry increase, suggesting relative resilience in its profit trajectory amid broader sector headwinds. This outlook highlights the company’s ability to navigate potential market slowdowns better than peers.